Bavituximab
Bavituximab Basic information
- Product Name:
- Bavituximab
- Synonyms:
-
- BAVITUXIMAB
- Tarvacin
- Research Grade Bavituximab (DGK10101)
- Anti-PS MAb 3G4
- Research Grade Bavituximab
- CAS:
- 648904-28-3
- MW:
- 0
- Mol File:
- Mol File
Bavituximab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Bavituximab Usage And Synthesis
Uses
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel.html" class="link-product" target="_blank">Paclitaxel (HY-B0015) and Carboplatin.html" class="link-product" target="_blank">Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
in vivo
Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2].
| Animal Model: | Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] |
| Dosage: | 100 μg/mouse (Bavituximab/β2GP1) |
| Administration: | Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) |
| Result: | Traced phosphatidylserine exposure in vivo in mice with tumors. |
References
[1] Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. DOI:10.1016/j.lungcan.2014.08.010
[2] Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. DOI:10.1245/s10434-016-5107-5
BavituximabSupplier
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com